Novartis, Astellas, GSK Ads Misbranded Drugs: FDA

Law360, New York (April 16, 2010, 2:37 PM EDT) -- The U.S. Food and Drug Administration said Friday that Novartis AG, Astellas Pharma Inc. and GlaxoSmithKline PLC misled consumers about the risks and effectiveness of drugs for osteoarthritis pain, overactive bladder and cancer.

The FDA publicized the letters that it sent to alert the pharmaceutical companies that they had misbranded their drugs in violation of the Federal Food, Drug and Cosmetic Act.

GSK's alleged misbranding relates to Arzerra, which is used to treat lymphocytic leukemia. The FDA objects to a Dec. 1 ad in the Journal...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.